title: Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies.
abstract: The aim of the study was to evaluate the influence of treatment with spiramycin on the increase of immunoglobulin G (IgG) titers and IgG avidity indexes (AI) in pregnant women with seroconversion from the beginning of therapy until delivery and after delivery. This group was compared with adult patients with recently acquired untreated toxoplasmosis. One hundred four samples from 32 pregnant women with seroconversion for toxoplasmosis and/or very low IgG AI were followed from the beginning of therapy with spiramycin until delivery. Twenty-nine women were further followed some months after delivery and interruption of therapy. Thirty-eight samples from 16 untreated, nonpregnant patients were evaluated as the control group. The Toxoplasma gondii-specific IgG antibody and the T. gondii-specific IgG AI were significantly delayed in pregnant women receiving therapy compared to nonpregnant, untreated controls, and the findings were consistent with the results of assays from two different manufacturers. The T. gondii-specific IgG AI increased in pregnant women after they gave birth. Avidity maturation is delayed during pregnancy and treatment, and low-avidity antibodies in pregnant women within 3 to 4 months cannot be taken as a sign of infection.
authors.affiliation: Department of Infectious Diseases, University of Pavia, Pavia, Italy. v.meroni@smatteo.pv.it
authors.forename: V
authors.initials: V
authors.lastname: Meroni
authors.forename: F
authors.initials: F
authors.lastname: Genco
authors.forename: C
authors.initials: C
authors.lastname: Tinelli
authors.forename: P
authors.initials: P
authors.lastname: Lanzarini
authors.forename: L
authors.initials: L
authors.lastname: Bollani
authors.forename: M
authors.initials: M
authors.lastname: Stronati
authors.forename: E
authors.initials: E
authors.lastname: Petersen
mesh_terms: D000328:Adult; D000913:Antibodies, Protozoan / Q000096:biosynthesis*; D000915:Antibody Affinity; D000918:Antibody Specificity; D016022:Case-Control Studies; D003049:Coccidiostats / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000276:immunology*; D015572:Spiramycin / Q000627:therapeutic use*; D013997:Time Factors; D014122:Toxoplasma / Q000276:immunology*; D014123:Toxoplasmosis / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000913:Antibodies, Protozoan; D003049:Coccidiostats; D007074:Immunoglobulin G; D015572:Spiramycin
references.citation: J Clin Microbiol. 2005 Jul;43(7):3481-3
references.pmid: 16000484
references.citation: Clin Exp Immunol. 1999 Sep;117(3):524-8
references.pmid: 10469057
references.citation: J Clin Microbiol. 1997 Aug;35(8):1972-7
references.pmid: 9230365
references.citation: J Clin Microbiol. 2003 Dec;41(12):5414-8
references.pmid: 14662919
references.citation: Eur J Clin Microbiol Infect Dis. 2006 Nov;25(11):687-93
references.pmid: 17024503
references.citation: Rev Inst Med Trop Sao Paulo. 1999 Sep-Oct;41(5):297-303
references.pmid: 10602544
references.citation: Pathol Biol (Paris). 1986 Mar;34(3):173-7
references.pmid: 3517786
references.citation: J Clin Microbiol. 2005 Apr;43(4):1570-4
references.pmid: 15814967
references.citation: Am J Obstet Gynecol. 2001 Jan;184(2):140-5
references.pmid: 11174493
references.citation: J Infect Dis. 1993 Mar;167(3):691-7
references.pmid: 8440939
references.citation: Diagn Microbiol Infect Dis. 1998 Oct;32(2):69-73
references.pmid: 9823527
references.citation: Eur J Pediatr. 2001 Sep;160(9):534-40
references.pmid: 11585075
references.citation: J Clin Microbiol. 1990 Sep;28(9):1928-33
references.pmid: 2229374
references.citation: Epidemiol Infect. 1994 Apr;112(2):399-408
references.pmid: 8150014
references.citation: Clin Diagn Lab Immunol. 2001 Sep;8(5):904-8
references.pmid: 11527801
references.citation: Clin Microbiol Infect. 1996 Aug;2(1):25-29
references.pmid: 11866807
references.citation: Clin Diagn Lab Immunol. 2000 Sep;7(5):781-7
references.pmid: 10973455
references.citation: Diagn Microbiol Infect Dis. 1998 Jan;30(1):25-30
references.pmid: 9488827
references.citation: Clin Vaccine Immunol. 2007 Mar;14(3):239-43
references.pmid: 17202303
references.citation: Pathol Biol (Paris). 1993 Feb;41(2):155-8
references.pmid: 8327266
references.citation: Clin Diagn Lab Immunol. 2000 May;7(3):384-9
references.pmid: 10799450
references.citation: J Infect Dis. 2001 Apr 15;183(8):1248-53
references.pmid: 11262207
references.citation: Clin Diagn Lab Immunol. 1999 Sep;6(5):725-8
references.pmid: 10473525
references.citation: J Clin Microbiol. 2002 Jul;40(7):2504-8
references.pmid: 12089270
references.citation: Arch Med Res. 2002 Nov-Dec;33(6):520-3
references.pmid: 12505095
references.citation: J Infect Dis. 1989 Apr;159(4):736-40
references.pmid: 2926163
references.citation: J Clin Microbiol. 1997 Jan;35(1):174-8
references.pmid: 8968902